Home » Stocks » Baxter International

Baxter International, Inc. (BAX)

Stock Price: $80.73 USD 0.36 (0.45%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $80.75 +0.02 (0.03%) Aug 7, 7:59 PM

Stock Price Chart

Key Info

Market Cap 40.87B
Revenue (ttm) 11.41B
Net Income (ttm) 924.00M
Shares Out 506.23M
EPS (ttm) 1.79
PE Ratio 45.10
Forward PE 26.04
Dividend $0.98
Dividend Yield 1.21%

Stock Quote

Trading Day Aug 7, 2020
Last Price $80.73
Previous Close $80.37
Change ($) 0.36
Change (%) 0.45%
Day's Open 80.49
Day's Range 79.99 - 81.11
Day's Volume 3,401,024
52-Week Range 69.10 - 95.19

More Stats

Market Cap 40.87B
Enterprise Value 43.65B
Earnings Date (est) Oct 21, 2020
Ex-Dividend Date Jun 4, 2020
Shares Outstanding 506.23M
Float 506.27M
EPS (basic) 1.81
EPS (diluted) 1.79
FCF / Share 2.91
Dividend $0.98
Dividend Yield 1.21%
Earnings Yield 2.22%
FCF Yield 3.62%
Payout Ratio 50.00%
Shares Short 5.19M
Short Ratio 1.65
Short % of Float 1.02%
Beta 0.79
PE Ratio 45.10
Forward PE 26.04
P/FCF Ratio 27.63
PS Ratio 3.58
PB Ratio 5.01
Revenue 11.41B
Operating Income 1.78B
Net Income 924.00M
Free Cash Flow 1.48B
Net Cash -2.78B
Net Cash / Share -5.49
Gross Margin 43.09%
Operating Margin 15.59%
Profit Margin 8.10%
FCF Margin 12.96%
ROA 7.19%
ROE 13.01%
ROIC 7.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (20)

Buy 14
Overweight 1
Hold 4
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

(18.51% upside)
Current: $80.73
Target: 95.67
*Average 12-month price target from 18 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth2.37%4.87%4.14%1.96%-7.01%13.87%-32.46%0.31%8.18%-
Gross Profit4,7614,7594,4744,1164,1464,5814,1627,1347,0465,958
Operating Income1,7721,5841,2887454496564962,7702,9462,136
Net Income1,0011,5466024,9659682,4972,0122,3262,2241,420
Shares Outstanding509534543546545542543551569590
Earnings Per Share1.932.831.089.011.764.563.664.183.882.39
EPS Growth-31.8%162.04%-88.01%411.93%-61.4%24.59%-12.44%7.73%62.34%-
Dividend Per Share0.850.730.610.5134.282.051.921.571.271.18
Dividend Growth16.44%19.67%20.79%-98.53%1572.34%6.77%22.29%24.11%7.2%-
Operating Cash Flow2,1042,0171,7141,6541,7713,2153,1983,1062,8173,003
Capital Expenditures-696-659-616-719-911-925-706-1,161-960-963
Free Cash Flow1,4081,3581,0989358602,2902,4921,9451,8572,040
Cash & Equivalents3,3351,8383,3942,8017,3612,9252,7333,2702,9052,685
Total Debt5,8603,4853,5122,7826,5079,0299,1665,9305,1954,387
Net Cash / Debt-2,525-1,647-11819.00854-6,104-6,433-2,660-2,290-1,702
Book Value7,8827,8449,1248,2908,8468,1208,4636,9386,5856,567
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Baxter International, Inc.
Country United States
Employees 50,000
CEO José E. Almeida

Stock Information

Ticker Symbol BAX
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NYSE: BAX


Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.